Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Efficacy of topical piperacillin/tazobactam (Tazocin) in the treatment of Pseudomonas aeruginosa-induced keratitis in rabbits

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Medical Cornea

Session Date/Time: Saturday 10/09/2016 | 09:30-11:00

Paper Time: 09:30

Venue: Poster Village: Pod 3

First Author: : A.Wan Ab Kadir MALAYSIA

Co Author(s): :    S. Ngu   V. Subrayan   R. Argawal        

Abstract Details

Purpose:

To evaluate the efficacy of topical Piperacillin/Tazobactam 10% (TazocinTM, Pfizer, Canada) in the treatment of experimental Pseudomonas aeruginosa induced keratitis in New Zealand white rabbits.

Setting:

Laboratory Animal Care Unit (LACU). University Technology MARA (UITM), Sungai Buloh Medical campus, Malaysia

Methods:

A total of 27 rabbits were observed, 24 and 108 hours after the intra-stromal inoculation of 0.1mF of P.aeruginosa. The rabbits were divided into three groups: each treated with Piperacillin/Tazobactam 10%, basic salt solution as placebo and Moxifloxacin 0.5%. The treatment commenced 12 hours after inoculation. The drops were instilled hourly for 12 hours and then 4 hourly for 3 days. Pre-treatment and post-treatment efficacies were scored based on infiltrate, edema, hyperaemia and eye discharge. In each treatment group of 18 eyes, it was divided to three groups for histopathology analysis, bacterial count and for tumor necrosis factor alpha levels.

Results:

Both the piperacillin/tazobactam and moxifloxacin groups were found to have lower post treatment score compared to placebo group. The clinical gain score of Piperacillin/Tazobactam group was better to Moxifloxacin group. Piperacillin/Tazobactam was found to effectively reduce the bacterial count. Piperacillin/Tazobactam group showed significant reduction of bacterial count compared to Moxifloxacin group. Moxifloxacin group had slightly better reduction of the inflammation score compared to the Piperacillin/Tazobactam group. Piperacillin/Tazobactam group demonstrated the lowest amount of TNFα level (mean 181.67±27.94pg/ml) followed by Moxifloxacin (649.17±38.85pg/ml). The level of TNFα in Piperacillin/Tazobactam group was reduced significantly compared to both the placebo and Moxifloxacin group with a mean difference of 661.83pg/ml in the former and 467.50pg/ml in the latter.

Conclusions:

Topical Piperacillin/Tazobactam 10% is more efficacious than topical Moxifloxacin 0.5% in the treatment of Pseudomonas aeruginosa (ATCC#27853).

Financial Disclosure:

NONE

Back to previous